Screener
Zevra Therapeutics, Inc. ZVRA Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
FAQ
- What is Zevra Therapeutics, Inc.'s total cost of revenue?
- Zevra Therapeutics, Inc. (ZVRA) reported total cost of revenue of $1.53M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s total cost of revenue changed year-over-year?
- Zevra Therapeutics, Inc.'s total cost of revenue decreased by 87.7% year-over-year, from $12.38M to $1.53M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s total cost of revenue?
- Over 4 years (2021 to 2025), Zevra Therapeutics, Inc.'s total cost of revenue has grown at a 68.2% compound annual growth rate (CAGR), from $2.06M to $16.48M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Zevra Therapeutics, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude